Forty Seven, Inc.
FTSV evidence brief
What we can confirm
- BioSniper Score:
- 5.0 / 10
- Lead Asset:
- fsi-174 (Preclinical)
What it means
What to watch
Prepared research question
What matters most for FTSV—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
fsi-174 (Preclinical)
Next Catalyst
—
Tracking 3 pipeline candidates for Forty Seven, Inc..
Run Forty Seven, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Forty Seven, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 1
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Frequently asked questions
What is Forty Seven, Inc.'s lead drug candidate?
Forty Seven, Inc.'s most advanced tracked candidate is fsi-174 (Preclinical) for stem cell transplantation conditioning.
Who is the CEO of Forty Seven, Inc.?
Genentech Inc is the chief executive officer of Forty Seven, Inc. (FTSV).
What therapeutic areas does Forty Seven, Inc. focus on?
Forty Seven, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.